September 01, 2016 4:43pm EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (Nasdaq: OPK) , today announced that senior
management will participate in the 11 th Annual Wells Fargo
Securities Healthcare Conference taking place September 7-8, 2016 in
Boston and the 9 th Annual Barrington Research Fall Investment
Conference taking place on September 8, 2016 in Chicago.
11 th Annual Wells Fargo Securities
Healthcare Conference
Date and Time: September 7, 2016, 11:05 AM EDT
Wells Fargo Healthcare Conference
Format: Company
presentation
Presenter: OPKO Health Senior Management
Barrington Research Fall Investment Conference
Date: September 8, 2016
Website: 9th
Annual Barrington Research Fall Investment Conference
Format: One-on-One
Meetings
The 11 th Annual Wells Fargo Securities Healthcare Conference
presentation will be webcast on OPKO Health’s Investor Relations page of
the corporate website at www.opko.com .
To access the live webcast, please log on to the OPKO site approximately
fifteen minutes before the presentation to register and download any
necessary audio software. The audio presentation will be available at
this link for a limited time after the live presentation.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation’s third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore prostate cancer test and the Claros
1 in-office immunoassay platform. Our pharmaceutical business
features RAYALDEE , an FDA approved treatment for SHPT in stage
3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched by
partner Tesaro and IV formulation PDUFA is January 2017). Our biologics
business includes hGH-CTP, a once-weekly human growth hormone injection
(in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug
for hemophilia (in Phase 2a) and a long acting oxyntomodulin for
diabetes and obesity (in Phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and an
active business development strategy. More information is available at www.opko.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901006500/en/
OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor Relations
or
Media
Rooney
& Associates
Terry Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released September 1, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page